ArticleBlood2013
Anti-hepcidin therapy for iron-restricted anemias.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial.BMC nephrology · 2018Trial
- Intestine-Specific Ferroportin Ablation Rescues from Systemic Iron Overload in Mice.Nutrients · 2026Article
- Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.Kidney international reports · 2021Review
- Management of the Jehovah's Witness in Obstetrics and Gynecology: A Comprehensive Medical, Ethical, and Legal Approach.Obstetrical & gynecological survey · 2016Review
- Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.Seminars in nephrology · 2016Review
- [Hepcidin for iron homeostasis and target therapy in ironrelated disorders].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Anemia in inflammatory bowel disease: an under-estimated problem?Frontiers in medicine · 2014Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
In this issue of Blood, Cooke et al demonstrate the potential of a fully human anti-hepcidin antibody as a novel therapeutic for iron-restricted anemias such as anemia of inflammation, cancer, or chronic kidney disease (formerly known as “anemia of chronic diseases”).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.